Initial monotherapy with eslicarbazepine acetate for the management of adult patients with focal epilepsy in clinical practice: a meta-analysis of observational studies.

Fecha de publicación: 01/05/2021 Fecha Ahead of Print: 01/06/2021

Autores de IIS La Fe

Vicente Enrique Villanueva Haba

Autor

Participantes ajenos a IIS La Fe

Fernandez-Anaya, Silvia
Serratosa, Jose M.
Rico-Villademoros, Fernando
Rojo, Rosa
Sarasa, Pilar

Abstract

To assess the effectiveness, overall tolerability of eslicarbazepine acetate (ESL) as an initial or early monotherapy treatment of adult patients with focal epilepsy under real-world practice conditions.

Datos de la publicación

ISSN/ISSNe:: 0020-7454, 1563-5279
Tipo:: Article
Páginas:: 1-11
DOI:: 10.1080/00207454.2021.1925667
PubMed:: 33993841
Factor de Impacto:: 0,440 SCImago ℠
Cuartil:: Q3 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Fernandez-Anaya, Silvia:: Medical Department, Laboratorios Bial, S.A., Madrid, Spain
Villanueva, Vicente:: Refractory Epilepsy Unit, Neurology Service, Hospital Universitario y Politécnico La Fe, Valencia, Spain
Serratosa, Jose M.:: Epilepsy Unit/Neurology Service, Hospital Universitario Fundación Jiménez Díaz and IIS Fundación Jiménez Díaz UAM, Madrid, Spain
Rico-Villademoros, Fernando:: Institute of Neurosciences, University of Granada, Granada, Spain

Cociente S.L., Madrid, Spain
Rojo, Rosa:: Faculty of Health Sciences, Alfonso X El Sabio University, Madrid, Spain
Sarasa, Pilar:: Medical Department, Laboratorios Bial, S.A., Madrid, Spain

Keywords

NEWLY-DIAGNOSED EPILEPSY; ANTIEPILEPTIC DRUGS; SAFETY; EFFICACY; TRIALS; CARBAMAZEPINE; MULTICENTER; EVOLUTION

Cita

Cita Bibliográfica